Prasterone in the treatment of mild to moderate urge incontinence: an observational study. Issue 8 (August 2022)

• Record Type: Journal Article
• Authors: Collà Ruvolo, Claudia; Gabrielli, Olimpia; Formisano, Carmen; Califano, Gianluigi; Manna, Paolo; Venturella, Roberta; Di Carlo, Costantino
• Is Part Of: Menopause. Volume 29:Issue 8(2022)
• Page Start: 957
• Page End: 962
• Publication Date: 2022-08
• Subjects: DHEA -- Menopause -- Prasterone -- Urinary urge incontinence; Menopause -- Periodicals; 618.175005
• DOI: 10.1097/GME.0000000000002007
• Languages: English
• ISSNs: 1072-3714

Abstract

Abstract: Objective: To assess the effects of prasterone compared with hyaluronic acid on symptoms of mild to moderate urinary urgency in women with genitourinary syndrome of menopause. Methods: This is an observational prospective cohort study. A total of 58 postmenopausal women were enrolled (from December 2019 to May 2021). Overactive Bladder Screener questionnaire, Patient Global Impression of Improvement questionnaire, International Consultation on Incontinence Questionnaire–Short Form, and International Quality of Life questionnaire were used. Results: Fifty-eight women, 29 (50%) and 29 (50%), were treated with prasterone and hyaluronic acid for 12 weeks, respectively. At the end of the study, 26 (89.7%) versus 3 (10.3%) women reported an improvement (Patient Global Impression of Improvement score ≤3) of the symptoms in the prasterone versus hyaluronic acid group. According to the International Consultation on Incontinence Questionnaire–Short Form, no statistically significant difference was recorded before treatment between the prasterone and hyaluronic acid groups (median, 12 [6-12] vs 11 [8-12]; P = 0.8). Conversely, a statistically significant difference was recorded after treatment between the two groups (median, 8 [5-11] vs 10 [8-11]; P = 0.03). According to the International Quality of Life, a statistically significantly lower median score was recorded in the prasterone compared with the hyaluronic acid group, before (73 [interquartile range {IQR}, 55-81] vs 89 [IQR, 67-94]; P < 0.01) and after (78 [IQR, 65-86] vs 87 [IQR, 72-99]; P = 0.04) treatment. Conclusions: The current observational study supports the hypothesis that prasterone might improve the severity of urinary urge incontinence in this set of women. However, these results need to be confirmed in further studies with a controlled design and a larger population.